Skip to content

US · CLRB · BIOTECHNOLOGY

Cellectar Biosciences, Inc. (CLRB) intrinsic value and stock valuation

$0.80as of 2026-11-21 · Mkt cap 8.04M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Cellectar Biosciences, Inc. DCF and intrinsic value

InvestorsCraft values CLRB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CLRB’s statements →

Cellectar Biosciences, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Florham Park, NJ 07932 cellectar.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-21.79M
20112025
Free cash flow
-$-23.12M
20112025
Total equity
$9.92M-29% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-22.98M-$-51.78M-$-38.96M-$-28.81M-$-24.13M
Net income-$-21.79M-$-44.58M-$-42.77M-$-31.79M-$-24.12M
EPSd-$-8.35M-$-35.95M-$-104.32M-$-132.46M-$-126.95M
Operating cash flow-$-23.12M-$-47.58M-$-32.38M-$-25.22M-$-22.57M
Capital expenditure-$-10K-$-100K-$-860K-$-230K-$-140K
Free cash flow-$-23.12M-$-47.69M-$-33.24M-$-25.45M-$-22.71M
Total assets$15M$25.5M$12.1M$21.6M$37.2M
Total debt$410K$490K$550K$600K$300K
Net debt-$-12.79M-$-22.79M-$-9.01M-$-19.26M-$-35.4M
Total equity$9.92M$14.3M-$-13.78M$9.54M$33.1M
Cash and short-term investments$13.2M$23.3M$9.56M$19.9M$35.7M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$210K$0.00$0.00$0.00$0.00
Gross profit-$-210K$0.00$0.00$0.00$0.00
Research and development expenses$11.5M$26.1M$27.3M$19.2M$17.6M
Selling, general and administrative expenses$11.5M$25.6M$11.7M$9.59M$6.54M
Other expenses-$-210K$0.00$0.00$0.00$0.00
Operating expenses$22.8M$51.8M$39M$28.8M$24.1M
Cost and expenses$23M$51.8M$39M$28.8M$24.1M
Interest income$440K$1.21M$390K$150K$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$210K$290K$190K$150K$150K
Ebitda-$-21.58M-$-44.22M-$-42.64M-$-31.7M-$-23.97M
Operating income-$-22.98M-$-51.78M-$-38.96M-$-28.81M-$-24.13M
Total other income/expenses, net$1.19M$7.26M-$-3.87M-$-3.04M$10K
Income before tax-$-21.79M-$-44.52M-$-42.83M-$-31.85M-$-24.12M
Income tax expense$0.00$70K-$-60K-$-60K$0.00
Net income-$-21.79M-$-44.58M-$-42.77M-$-31.79M-$-24.12M
Weighted average shares outstanding$2.61M$1.22M$410K$240K$190K
Weighted average diluted shares outstanding$2.61M$1.24M$410K$240K$190K
Balance sheet
20252024202320222021
Cash and short-term investments$13.2M$23.3M$9.56M$19.9M$35.7M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$14M$24.3M$10.5M$20.5M$36.6M
Property, plant and equipment, net$910K$1.19M$1.59M$980K$550K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$940K$1.22M$1.62M$1.06M$630K
Total assets$15M$25.5M$12.1M$21.6M$37.2M
Accounts payable$1.44M$4.11M$5.62M$2.56M$1.42M
Short-term debt$100K$80K$60K$50K$140K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$4.75M$9.39M$25.4M$11.5M$3.99M
Long-term debt$310K$410K$490K$550K$170K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$310K$1.79M$490K$550K$170K
Capital lease obligations$410K$490K$550K$600K$300K
Total liabilities$5.06M$11.2M$25.9M$12.1M$4.16M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-269.13M-$-247.34M-$-202.76M-$-159.99M-$-150.9M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$9.92M$14.3M-$-13.78M$9.54M$33.1M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$410K$490K$550K$600K$300K
Net debt-$-12.79M-$-22.79M-$-9.01M-$-19.26M-$-35.4M
Cash flow statement
20252024202320222021
Net income-$-21.79M-$-44.58M-$-42.77M-$-28.6M-$-24.12M
Depreciation and amortization$210K$290K$190K$150K$150K
Stock-based compensation$2.26M$4.27M$2.41M$1.45M$1.12M
Change in working capital-$-3.13M-$-1.73M$3.48M$1.68M$200K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-3.16M-$-1.59M$0.00$0.00$0.00
Net cash provided by operating activities-$-23.12M-$-47.58M-$-32.38M-$-25.22M-$-22.57M
Investments in property, plant and equipment-$-10K-$-100K-$-860K-$-230K-$-140K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-10K-$-100K-$-860K-$-230K-$-140K
Common stock issued$13M$61.4M$0.00$9.61M$30K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$13M$61.4M$22.9M$9.61M$1.25M
Net change in cash-$-10.09M$13.7M-$-10.3M-$-15.84M-$-21.46M
Cash at end of period$13.2M$23.3M$9.56M$19.9M$35.7M
Operating cash flow-$-23.12M-$-47.58M-$-32.38M-$-25.22M-$-22.57M
Capital expenditure-$-10K-$-100K-$-860K-$-230K-$-140K
Free cash flow-$-23.12M-$-47.69M-$-33.24M-$-25.45M-$-22.71M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Cellectar Biosciences, Inc.

        Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.

        CEO
        James V. Caruso
        Employees
        11
        Beta
        0.55

        Explore

        Frequently asked questions

        What is the intrinsic value of Cellectar Biosciences, Inc. (CLRB)?

        InvestorsCraft does not currently publish an intrinsic value for CLRB. How the IC value is calculated.

        Is CLRB undervalued?

        InvestorsCraft does not publish an undervaluation signal for CLRB at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.